



PRESS RELEASE

EDEN BIODESIGN AND BOREAN PHARMA APS SIGN DEAL TO DEVELOP NOVEL THERAPEUTIC CANDIDATE FOR THE TREATMENT OF CANCER

Liverpool, UK and Aarhus, Denmark; 10th September 2007: Eden Biodesign Ltd, an expert provider of development and manufacturing services for new biopharmaceutical medicines, and Borean Pharma ApS announced today that they have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in key preclinical studies. The project is expected to complete early in 2008.

MBP-DC-SIGN is one of Borean's products to be based on the Mannose-Binding protein (MBP) platform. The MBP platform is delivering a series of highly potent therapeutics for the treatment of cancers, and is the only scaffold that can induce complement-induced lysis.

"Working with Eden Biodesign will allow us to rapidly progress the development of this promising drug candidate" commented Dr Johanna Holldack, CEO of Borean Pharma ApS. "We are delighted to have this project conducted at Eden Biodesign's state of the art facility in Liverpool."

"Our facilities are designed to rapidly produce high quality biopharmaceuticals and we're really pleased to have been selected by Borean Pharma ApS, based on our experience and expertise which will assist them in the acceleration of the development of the MBP-DC-SIGN" added Dr Crawford Brown, CEO of Eden Biodesign.

The agreement with Borean Pharma is the fourth contract to be announced by Eden Biodesign in the past 7 weeks, following announcements for cGMP manufacturing and development projects with CRUK, University of Birmingham and UMIP.

Ends

For further information contact:

Stéphanie Monfront, DeFacto Communications Ltd +44 (0)20 7861 3838
Email s.monfront@defacto.com

Dr Douglas Pretsell, Account Director, Munich Bureau Chief - Northbank Communications
+49 (0)89 57 00 18 06 Email d.pretsell@northbankcommunications.com



BOREAN PHARMA



Notes to editors:

Borean Pharma

Borean Pharma was established with the objective to develop a new generation of pharmaceutical protein products. Borean Pharma has a powerful protein engineering platform for the discovery of proteins with the potential to provide greatly improved successors to existing protein pharmaceuticals and antibody therapeutics. For further information please visit the website at www.boreanpharma.com

Eden Biodesign

Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides 'state of the art' development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit www.edenbiodesign.com.

The National Biomanufacturing Centre

The £34.25 million National Biomanufacturing Centre which was officially opened in November 2006, is a Government-funded initiative led by the Northwest Regional Development Agency (NWDA) additionally funded through the European Regional Development Fund (ERDF) and the Department of Trade and Industry (DTI) and aims to establish England's Northwest as one of the foremost biomanufacturing centres in Europe.

The centre provides the expertise and facilities to support new and existing biotechnology companies, offering product development services designed to fill in the skill and resource gaps that exist within these organisations. It also provides training in biomanufacturing and analytical sciences, delivering the skilled workforce required to expand the UK biopharmaceutical sector.

There is also an Access Fund of nearly £3 million funded by the Department of Trade and Industry and the European Regional Development Fund, which is available to qualifying small-to-medium companies and academic groups in the biotechnology sector to assist them in purchasing development and clinical manufacturing services from the Centre. www.biomanufacturing.co.uk